SHR-5495 / Jiangsu Hengrui Pharma - LARVOL DELTA

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Hengrui Medicine’s two new anti-tumor drugs have been approved for clinical trials. No similar products have been launched at home or abroad. [Google translation] (163.com) - "...On the evening of September 20, Hengrui Pharmaceuticals issued two announcements. Two new anti-tumor drugs, SHR-2005 injection and SHR-5495 for injection, were approved for clinical trials....SHR-2005...The approved clinical trial is for single-agent use in bladder cancer. Up to now, Hengrui Medicine has invested a total of approximately 37.93 million yuan in research and development expenses on SHR-2005 injection-related projects...SHR-5495...The approved clinical trial is for single-agent use in advanced malignant tumors....Hengrui Medicine has invested a total of approximately 24 million yuan in research and research and development expenses for this drug."

Commercial • New trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor